Mr. Chair, that would be the principal responsibility of Health Canada. Health Canada has been conducting the interface here with the provincial ministries of health, with the health community. We at NRCan have been focused on the supply side of the equation. We obviously talk to Health Canada and we have those kinds of discussions, and we appreciate that the fragile situation globally is entailing higher costs, but you would need to address the question to Health Canada in terms of jurisdiction by jurisdiction, or actual higher costs.
It is also not a trivial matter estimating that, because for example, even prior to the NRU shutdown, there were some price increases announced by some of the suppliers of technetium-99. So there were already some market developments prior to the shutdown of the NRU, and one would have to disaggregate what is truly the cause of the NRU shutdown versus what may be other market factors in play.